The Fourth International Meeting on Clinical Pharmacology in Psychiatry was held in Bethesda, Maryland on 5-8 September 1985 and was dedicated to the memory of Dr. Earl Usdin. Earl was one of the organizers of the three previous meetings held in Chicago (1979), Troms0 (1980), and Odense (1982). During the organization of the fourth meeting Earl became ill and had to relinquish his role as one of the principal organizers. It is safe to conclude that there was no better, or more professional, or more efficient an organizer of scientific meetings in the field of neuropharmacology and psychiatry than Earl U sdin, and it was quite a task for the remaining organizers to fill the void left when he withdrew from this one. Those of us who have organized previous meetings with Earl were struck by how much more difficult our work became without him. This obviously speaks well for his subtle (and at times not so subtle) organizational skills. Nevertheless, in Earl's memory the organizers proceeded to invite a group of internationally renowned neuropsychopharmacologists to address the problem of selectivity in psychotropic drug action and to try to reconcile the amazing advances in basic preclinical neuropsychopharmacology with the problem of clinical specificity encountered by the psychiatrist.
Table of ContentsMolecular Pharmacology in Drug Development.- Molecular Modeling in Drug Design.- Synthesis of New Peptides Based on Models of Receptor-Bound Conformation.- Molecular Approach to the Mechanism of Action of Antidepressant Drugs.- Anxiolytics.- Modulation of the Benzodiazepine-GABA Receptor Chloride Ionophore Complex by Multiple Allosteric Sites: Evidence for a Barbiturate “Receptor”.- ?-Carbolines: New Insights into the Clinical Pharmacology of Benzodiazepine Receptor Ligands.- Pharmacodynamic Approaches to Benzodiazepine Action in Man.- Correlating Pharmacokinetics and Pharmacodynamics of Benzodiazepines: Problems and Assumptions.- Benzodiazepine-Serotonin Interactions in Man.- Comparative Pharmacodynamics of Benzodiazepines.- Abuse Liability of Triazolam: Experimental Measurements in Animals and Humans.- Clinical Studies of “Specific” Anxiolytics as Therapeutic Agents.- Antidepressants.- Regulation of Beta Adrenergic and Serotonin-S2 Receptors in Brain by Electroconvulsive Shock and Serotonin.- ?2-Adrenoceptor Antagonists as Antidepressants: The Search for Selectivity.- GABA Synapses, Depression, and Antidepressant Drugs.- Antidepressant Monoamine Oxidase Inhibitors Enhance Serotonin but not Norepinephrine Neurotransmission.- Selective Amine Oxidase Inhibitors: Basic to Clinical Studies and Back.- Therapeutic Effect of Selective 5HT Reuptake Inhibitors in Comparison with Tricyclic Antidepressants.- Accidental Antidepressants: Search for Specific Action.- Antidepressants and EEG Sleep: Search for Specificity.- Possible Teratogenic Effects of Imipramine in the Rat.- Pharmacological Specificity Is Not the Same as Clinical Selectivity.- Pharmacokinetic Considerations Relevant to the Pharmacodynamics of Antidepressants.- Receptor Assay Based on 3H-Imipramine Binding.- Neuroleptics.- Pharmacological Validation of the Two-Dopamine-Receptor Hypothesis.- Differential Regulation of Dopamine-D2 and Serotonin-S2 Receptors by Chronic Treatment with the Serotonin-S2 Antagonists, Ritanserin and Setoperone.- Chronic Neuroleptic Effects on Dopamine Neuron Activity: A Model for Predicting Therapeutic Efficacy and Side Effects?.- Effect of Selective D1 and D2 Dopamine Receptor Antagonists and Agonists in Cebus Monkeys: Implications for Acute and Tardive Dyskinesias. A Preliminary Report.- Neuroleptic-lnduced Parkinsonism Increases with Repeated Treatment in Monkeys.- Biochemical Alterations Produced by Neuroleptics in Man: Studies of Plasma Homo vanillic Acid in Schizophrenic Patients.- Effect of Neuroleptics on the Schizophrenic Syndrome.- Pharmacokinetic and Pharmacodynamic Factors Causing Variability in Response to Neuroleptic Drugs.- List of Participants.